Introduction 38
In the continued absence of an effective vaccine against HIV, development of vaginally-39 administered microbicide products remains a priority biomedical strategy aimed at addressing 40 the urgent and yet unmet need for reducing women's risk of sexually-transmitted infection with 41 HIV, particularly in developing countries (1, 2) . Small-molecule antiretrovirals -most notably 42 dapivirine (3-10), tenofovir (11) (12) (13) (14) (15) and tenofovir disoproxil fumarate (14, (16) (17) (18) (19) -are currently 43 the primary focus for the microbicide field, offering relatively low costs for synthesis of the active 44 pharmaceutical ingredient, a diverse range of practical formulation options, and potent antiviral 45 activity targeted at the reverse transcription step in the HIV replication cycle. However, there is 46 a strong rationale for the development of new antiviral agents for HIV prevention that overcome 47 some of the disadvantages associated with these lead candidate, small molecule, antiretroviral 48 microbicides, including the potential emergence of resistant viruses and their post-entry 49 mechanism of action (20-22). By comparison, many of the larger molecular weight 50 biopharmaceutical compounds that have been or are being considered as vaginal microbicides -51 including cyanovirin-N (23-25), Griffithsin (26, 27) , 29) , T-1249 peptide (30), 52 retrocyclin RC-101 (31) and monoclonal antibodies (32-34) -generally exhibit greater antiviral 53 potency than current small molecule antiretrovirals (at least in in vitro models) and usually act 54 prior to viral entry into the host cell by either directly targeting the free virus or by blocking cell 55 receptors (35) (36) (37) (38) . In this study, vaginally-administered 5P12-RANTES was measured following single dose aqueous 148 gel administration in sheep. The pseudoplastic behaviour of the gel, and indeed the general 149 magnitude of the viscosity values, is typical of gels intended for vaginal drug administration, as 150 reported previously for aqueous hydroxyethylcellulose gels and non-aqueous silicone gels (50-151 57). From a clinical perspective, pseudoplasticity offers certain advantages and disadvantages.
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Gels will likely spread more easily at higher shear rates (during coitus) or following dilution with 153 vaginal fluids or semen leading to increased distribution in the vaginal environment and 154 enhanced tissue coverage (51). However, there is also an increased likelihood of leakage of the 155 gel from the vagina (58-60). The syringeability values are higher than values reported previously 156 for other water-based vaginal gels (e.g. 35-67 N.mm for rheologically structured vehicles (46, 157 49), and 4.4 N.mm for Replens™ vaginal moisturiser (49) ), although the test method used in this 158 study involved testing expulsion of a greater quantity of gel (4 g vs. 3 g) through a greater plunger 159 distance (50 mm vs. 30 mm) and the use of a commercial plastic vaginal applicator rather than a 160 general purpose disposable plastic syringe. All things considered, the syringeability values 161 measured translate into ease and practicality of gel product administration, as verified by the 162 animal handlers.
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In the in vitro release testing study, a relatively low release/recovery value (~50%) for 5P12-165 RANTES was noted for the high dose gel, compared to >90% release from the low and 5P12-RANTES has previously been shown to be stable by in vitro cell fusion assay (i) when In vitro dissolution testing of 5P12-RANTES gels 283 Simulated vaginal fluid (SVF), modified to include an increased BSA concentration (0.1% w/w) to 284 reduce adsorption of 5P12-RANTES to glassware, was prepared according to previously described 285 methods (75, 76). The SVF was filtered immediately after preparation (sterile Millex-GS Syringe 286 Filter Unit, mixed cellulose ester membrane, Millipore, UK) and stored for a maximum of 3 days 287 at 4-6°C prior to use. The concentration of 5P12-RANTES in the SVF release medium was measured by ELISA using the 297 Human CCL5/RANTES ELISA kit (R&D Systems, UK, cat no. DRN00B). Samples were analysed per 298 the manufacturer's instructions after appropriate dilutions were made to ensure concentrations 299 fell within the 0.002-2 ng/mL range of the kit. Absorbance was measured at 450 nm using a 300 microplate reader (Enspire Multimode Plate Reader, PerkinElmer, USA) and the optical density 301 at 570 nm was subtracted to correct for plate imperfections. The standard curve was transformed 302 to a four-parameter logistic (4-PL) curve-fit and sample concentrations were calculated relative 303 to it. Concentration readings were subsequently multiplied by the appropriate dilution factor. 
